{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T22:08:48Z","timestamp":1744150128169},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,6,8]],"date-time":"2018-06-08T00:00:00Z","timestamp":1528416000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12885-018-4561-9","type":"journal-article","created":{"date-parts":[[2018,6,8]],"date-time":"2018-06-08T01:14:56Z","timestamp":1528420496000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["A patient with plasmablastic lymphoma achieving long-term complete remission after thalidomide-dexamethasone induction and double autologous stem cell transplantation: a case report"],"prefix":"10.1186","volume":"18","author":[{"given":"Alessandro","family":"Broccoli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Nanni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vittorio","family":"Stefoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudio","family":"Agostinelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Argnani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Cavo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pier Luigi","family":"Zinzani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,6,8]]},"reference":[{"key":"4561_CR1","unstructured":"Campo E, Stein H, Harris NL. Plasmablastic lymphoma In: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, Swerdlow SH, Campo E, Harris NL, et al, Eds. IARC Press, Lyon, France, Revised 4th edition; 2017. p. 317, 321\u2013322."},{"key":"4561_CR2","first-page":"826","volume":"89","author":"M Cavo","year":"2004","unstructured":"Cavo M, Zamagni E, Tosi P, Cellini C, Cangini D, Tacchetti P, et al. First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma. Haematologica. 2004;89:826\u201331.","journal-title":"Haematologica"},{"key":"4561_CR3","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.1182\/blood-2014-10-567479","volume":"125","author":"JJ Castillo","year":"2015","unstructured":"Castillo JJ, Bibas M, Miranda RN. The biology and treatment of plasmablastic lymphoma. Blood. 2015;125:2323\u201330.","journal-title":"Blood"},{"key":"4561_CR4","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1038\/modpathol.2010.72","volume":"23","author":"L Taddesse-Heath","year":"2010","unstructured":"Taddesse-Heath L, Meloni-Ehrig A, Scheerle J, Kelly JC, Jaffe ES. Plasmablastic lymphoma with MYC translocation: evidence for a common pathway in the generation of plasmablastic features. Mod Pathol. 2010;23:991\u20139.","journal-title":"Mod Pathol"},{"key":"4561_CR5","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1097\/PAS.0b013e3181f3e29f","volume":"34","author":"A Valera","year":"2010","unstructured":"Valera A, Balagu\u00e9 O, Colomo L, Mart\u00ednez A, Delabie J, Taddesse-Heath L, et al. Ig\/MYC rearrangements are the main cytogenetic alteration in plasmablastic lymphomas. Am J Surg Pathol. 2010;34:1686\u201394.","journal-title":"Am J Surg Pathol"},{"key":"4561_CR6","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1634\/theoncologist.2009-0304","volume":"15","author":"JJ Castillo","year":"2010","unstructured":"Castillo JJ, Winer ES, Stachurski D, Perez K, Jabbour M, Milani C, et al. Prognostic factors in chemotherapy-treated patients with HIV-associated plasmablastic lymphoma. Oncologist. 2010;15:293\u20139.","journal-title":"Oncologist"},{"key":"4561_CR7","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1016\/j.bbmt.2014.06.009","volume":"20","author":"MM Al-Malki","year":"2014","unstructured":"Al-Malki MM, Castillo JJ, Sloan JM, Re A. Hematopoietic stem cell transplantation for plasmablastic lymphoma: a review. Biol Blood Marrow Transplant. 2014;20:1877\u201384.","journal-title":"Biol Blood Marrow Transplant"},{"key":"4561_CR8","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1159\/000350325","volume":"36","author":"NS Saba","year":"2013","unstructured":"Saba NS, Dang D, Saba J, Cao C, Janbain M, Maalouf B, et al. Bortezomib in plasmablastic lymphoma: a case report and review of the literature. Onkologie. 2013;36:287\u201391.","journal-title":"Onkologie"},{"key":"4561_CR9","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/ejh.12286","volume":"93","author":"M Yan","year":"2014","unstructured":"Yan M, dong Z, Zhao F, Chauncey T, Deauna-Limayo D, Wang-Rodriguez J, et al. CD20-positive plasmablastic lymphoma with excellent response to bortezomib combined with rituximab. Eur J Haematol. 2014;93:77\u201380.","journal-title":"Eur J Haematol"},{"key":"4561_CR10","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1111\/bjh.13300","volume":"169","author":"JJ Castillo","year":"2015","unstructured":"Castillo JJ, Reagan JL, Sikov WM, Winer ES. Bortezomib in combination with infusional dose-adjusted EPOCH for the treatment of plasmablastic lymphoma. Br J Haematol. 2015;169:352\u20135.","journal-title":"Br J Haematol"},{"key":"4561_CR11","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s40364-015-0053-0","volume":"3","author":"M Hirosawa","year":"2015","unstructured":"Hirosawa M, Morimoto H, Shibuya R, Shimajiri S, Tsukada J. A striking response of plasmablastic lymphoma of the oral cavity to bortezomib: a case report. Biomark Res. 2015;3:28.","journal-title":"Biomark Res"},{"key":"4561_CR12","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1007\/s00277-016-2601-6","volume":"95","author":"PL Fedele","year":"2016","unstructured":"Fedele PL, Gregory GP, Gilbertson M, Shortt J, Kumar B, Opat S, et al. Infusional dose-adjusted EPOCH plus bortezomib for the treatment of plasmablastic lymphoma. Ann Hematol. 2016;95:667\u20138.","journal-title":"Ann Hematol"},{"key":"4561_CR13","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1111\/ejh.12732","volume":"96","author":"E Cencini","year":"2016","unstructured":"Cencini E, Fabbri A, Guerrini S, Mazzei MA, Rossi V, Bocchia M. Long-term remission in a case of plasmablastic lymphoma treated with COMP (cyclophosphamide, liposomal doxorubicin, vincristine, prednisone) and bortezomib. Eur J Haematol. 2016;96:650\u20134.","journal-title":"Eur J Haematol"},{"key":"4561_CR14","doi-asserted-by":"publisher","first-page":"2986","DOI":"10.3109\/10428194.2015.1016931","volume":"56","author":"S Carras","year":"2015","unstructured":"Carras S, Regny C, Peoc\u2019h M, Gervasoni J, Gressin R, Cahn JY, et al. Dramatic efficacy of low dose lenalidomide as single agent in a patient with refractory gastric non-human immunodeficiency virus-associated plasmablastic lymphoma. Leuk Lymphoma. 2015;56:2986\u20138.","journal-title":"Leuk Lymphoma"},{"key":"4561_CR15","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1159\/000455146","volume":"40","author":"JM Schmit","year":"2017","unstructured":"Schmit JM, DeLaune J, Norkin M, Grosbach A. A case of plasmablastic lymphoma achieving complete response and durable remission after lenalidomide-based therapy. Oncol Rest Treat. 2017;40:46\u20138.","journal-title":"Oncol Rest Treat"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-018-4561-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-018-4561-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-018-4561-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T07:03:46Z","timestamp":1661411026000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-018-4561-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,8]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["4561"],"URL":"https:\/\/doi.org\/10.1186\/s12885-018-4561-9","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,8]]},"assertion":[{"value":"18 January 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This retrospective study was approved by our institutional board and by our Ethical Committee (Comitato Etico Indipendente Policlinico S.Orsola-Malpighi di Bologna) and has been performed in accordance with the ethical standards of the Declaration of Helsinki.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The patient provided written informed consent to publish her data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"645"}}